VivoSeq
Immunology

Allergic Disease

32

Pipeline Programs↗

1

Active Trials↗

23

Companies Involved↗

Allergic Disease is a moderately active landscape with 32 programs across 23 companies. The most active players are AstraZeneca, Siolta Therapeutics, Inc., Hyundai Pharmaceutical Co., LTD.. 20 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

27/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1S

Siolta Therapeutics, Inc.

1 program

Phase 2H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 2A

Amphastar Pharmaceuticals, Inc.

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2Roche logo

Roche

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

28 of 33 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody412%Protein / enzyme13%

Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 100% of 37 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed6 · 60%
Unknown status3 · 30%
Recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life
Recruiting·—·N/A·NCT06535087·600 enrolled
Probiotics and Allergic Diseases
Completed·GGenMont Biotech Incorporation·N/A·NCT01635738·240 enrolled
A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases
Completed·YYuhan Corporation·Phase 1·NCT05061524·68 enrolled
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases
Completed·YYuhan Corporation·Phase 1·NCT05564221·46 enrolled
Functional Activity of Airway Eosinophils in Allergic Disease
Completed·UUniversity of Wisconsin, Madison·N/A·NCT01026532·31 enrolled
A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases
Completed·YYuhan Corporation·Phase 1·NCT05960708·30 enrolled
Allergic Disease Onset Prevention Study
Completed·SSiolta Therapeutics, Inc.·Phase 1/2·NCT05003804·283 enrolled
Traditional Chinese Medicine on Gut Microbiota and Allergic Diseases
Unknown status·—·Phase 3·NCT03033290·60 enrolled
Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008
Unknown status·UUniversity of Helsinki·Phase 2/3·NCT00298337
Study on the Correlation Between Intestinal Microecology and Allergic Diseases in Children
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04938700·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)